MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.71
+0.01
+0.18%
Closed 16:00 09/21 EDT
OPEN
5.72
PREV CLOSE
5.70
HIGH
5.84
LOW
5.71
VOLUME
94.77K
TURNOVER
--
52 WEEK HIGH
10.25
52 WEEK LOW
4.201
MARKET CAP
132.57M
P/E (TTM)
-1.6458
1D
5D
1M
3M
1Y
5Y
What Kind Of Shareholders Own SCYNEXIS, Inc. (NASDAQ:SCYX)?
A look at the shareholders of SCYNEXIS, Inc. ( NASDAQ:SCYX ) can tell us which group is most powerful. Generally...
Simply Wall St. · 1d ago
BRIEF-Scynexis Announces Hansoh Pharma's China Application For Trial Of Vaginal Yeast Infection Treatment
reuters.com · 09/13 12:48
SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China regionJERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a bio...
GlobeNewswire · 09/13 12:30
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences...
GlobeNewswire · 09/08 12:30
2 Small-Cap Healthcare Stocks Wall Street Predicts Will Rally by More Than 200%
StockNews.com · 08/31 11:48
SCYNEXIS Q2 EPS $(0.22) Up From $(0.64) YoY
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.22) per share. This is a 65.63 percent increase over losses of $(0.64) per share from the same period last year.
Benzinga · 08/16 12:20
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S. patent protectionU.S. commer...
GlobeNewswire · 08/16 12:00
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 77% over the last five years
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
Simply Wall St. · 08/13 09:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCYX. Analyze the recent business situations of SCYNEXIS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCYX stock price target is 24.36 with a high estimate of 35.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 19.70M
% Owned: 84.86%
Shares Outstanding: 23.22M
TypeInstitutionsShares
Increased
22
1.33M
New
12
2.08M
Decreased
3
103.17K
Sold Out
9
309.18K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
Pamela Kirby
President/Chief Executive Officer/Director
Marco Taglietti
Chief Financial Officer
Eric Francois
Vice President/Director of Sales/Director of Marketing
Jim Maffezzoli
Vice President
Nkechi Azie
General Counsel
Scott Sukenick
Other
David Angulo
Other
Christine Coyne
Director
Armando Anido
Director
Laurent Arthaud
Director
Steven Gilman
Director
Ann Hanham
Director
David Hastings
Director
Patrick Langlois
Director
Guy Macdonald
Director
Jean-Yves Nothias
Director
Philippe Tinmouth
No Data
About SCYX
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous oral agent for multiple fungal indications in both the community and hospital settings. It has received the acceptance letter from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). The FDA has conditionally approved Brexafemme as the brand name for oral ibrexafungerp for vaginal yeast infections. It is also continuing late-stage clinical development for the prevention of recurrent VVC, as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.